Printer Friendly

CHAIRMAN OF AMERICAN BIOGENETIC SCIENCES ADDRESSES RUSSIAN SCIENTISTS

CHAIRMAN OF AMERICAN BIOGENETIC SCIENCES ADDRESSES RUSSIAN SCIENTISTS
 ST. PETERSBURG, Russia, May 6 /PRNewswire/ -- Alfred J. Roach, chairman of the board of American Biogenetic Sciences, Inc. (ABS) (NASDAQ: MABXA), an international business leader, yesterday addressed a meeting of Russia's leading scientists, political, business and student leaders in St. Petersburg.
 The international forum was held at the St. Petersburg Institute for Trade and Commerce and was co-sponsored by the International Trade Resource Center and the University of Texas-Dallas under the sponsorship of Gov. Ann Richards of Texas, Mayor Steve Bartlett of Dallas and Mayor Anatoly Sobchak of St. Petersburg.
 During Roach's far ranging keynote address on Russia -- past, present and future -- the gathering become emotionally charged. A standing ovation followed the conclusion of his address.
 A young Russian professor attending the forum stated, "Mr. Roach today made me again proud to be a Russian."
 The speech pointed out the many contributions Russia has made to the world in space, medicine and general technology. His speech also covered the rich history of Russia in music, literature, art and dance.
 He called on the Western world to assist Russia during this bridge period with skilled business leaders, trade and financial experts and investment capital. "This is a 'window of opportunity' the leaders and free people of the free world can't ignore," Roach stated to the future leaders of Russia.
 Roach's address at the institute was followed by a series of private meetings with high level executives that took place in St. Petersburg and in Moscow to explore the possibility of joint ventures primarily in the fields of biogenetic sciences and technology.
 During a meeting with the Institute of Experimental Medicine of the Russian Academy Medical Service, Department of Molecular Microbiology, chief of staff Dr. A.A. Totolian stated: "We're excited with the opportunity of negotiating a joint venture with American Biogenetic Sciences in the field of biotechnology."
 Roach's company, American Biogenetic Sciences, Inc., a global corporation with a market capitalization of over $100 million, is involved in medical research and development with the University of Notre Dame and Trinity College, Dublin, Ireland. The company also has research projects with Yale, Johns Hopkins, and the University of Galway, Ireland.
 The primary focus of ABS research centers on using monoclonal antibodies in diagnosing, treating and preventing cardiovascular diseases.
 ABS is also developing a monoclonal antibody that could facilitate early diagnosis and treatment of Alzheimer's disease. Another research effort centers on developing a recombinant vaccine for Hepatitis A.
 Recently in Dublin and in New York City, Roach announced that ABS is financially backing a medical research team from the Irish National Institute of Breast Cancer Research. The team is pioneering a breakthrough product for early breast cancer detection.
 Roach is also chairman of TII Industries, an American Stock Exchange-listed high-technology company specializing in the design, manufacture and sale of telephone network interface and protection products, surge protection and specialized electronic devices, principally for use in the telecommunications industry.
 Roach, founder of both TII and ABS, is active in global business and international relations. His credo over the years has always been: "There are still so many ideas to be tried."
 -0- 5/6/92
 /CONTACT: Fran Giambanco of ABS, 516-789-2600; or Phil Fried of the Dilenschneider Group, 212-922-0900, for ABS/
 (MABXA) CO: American Biogenetic Sciences, Inc. ST: New York IN: MTC SU:


GK-CK -- NY025 -- 7004 05/06/92 10:42 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 6, 1992
Words:565
Previous Article:GENESCO COMPLETES MITRE SPORTS UK ACQUISITION
Next Article:'SESAME STREET'S' BOB McGRATH TO REHEARSE WITH LOCAL STUDENTS FOR NEW PINE KNOB SEASON OPENER
Topics:


Related Articles
AMERICAN BIOGENETIC SCIENCES RECEIVES $10.3 MILLION IN WARRANT EXERCISE
AMERICAN BIOGENETIC SCIENCES SIGNS LICENSE AGREEMENT WITH YAMANOUCHI PHARMACEUTICAL
AMERICAN BIOGENETIC SCIENCES FIBRINOGEN ANTIBODY PATENT NO. 5,091,512 ISSUED
AMERICAN BIOGENETIC SCIENCES RECEIVES $15.5 MILLION FROM 100 PERCENT EXERCISE OF WARRANTS
CHANGE IN PRESIDENCY OF AMERICAN BIOGENETIC SCIENCES
AMERICAN BIOGENETIC SCIENCES CEO SENDS UPDATE LETTER TO SHAREHOLDERS
AMERICAN BIOGENETIC SCIENCES SENDS LETTER TO SHAREHOLDERS
DAVID L. NEER APPOINTED SENIOR VICE PRESIDENT - BUSINESS DEVELOPMENT, AMERICAN BIOGENETIC SCIENCES, INC.
AMERICAN BIOGENETIC SCIENCES, INC. COMPLETES $8.5 MILLION PRIVATE PLACEMENT
American Biogenetic Sciences Inc. Moves Worldwide Research-And-Development Headquarters to Boston University's BioSquare

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters